ANX007-GLA-02
30 evidence topics · 4 sources
Objective
Registered primary, secondary, and exploratory objectives of the phase 1b study
Published objective of the repeat-dose study
“The phase Ib study was a double-masked, randomized, sham-controlled trial evaluating 2 dose levels of ANX007 (2.5 mg and 5 mg) to determine the safety and tolerability (primary objectives) of 2 repeat monthly IVT injections (NCT04188015).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Location and study date
Registry dates for the phase 1b study
| Milestone | Registry record |
|---|---|
| Study start (actual) | “2018-07-25” |
| Primary completion (actual) | “2019-06-03” |
| Study completion (actual) | “2019-06-03” |
Study design
Registered design of the phase 1b study
Eligibility criteria
Published inclusion criteria for the phase 1b study
“In the phase Ib study, eligible patients were aged ≥ 18 years, of either sex, with primary open-angle glaucoma with a mean deviation of −3 to −24 decibels (dB) on a reliable visual field test using the Humphrey field analyzer in the study eye as determined at screening, and an IOP < 21 mm Hg at screening and day 1, with no change to the IOP treatment regimen anticipated throughout study participation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Registered exclusion criteria for the phase 1b study
Treatment
Repeat-dose randomization and injection volumes
“In the repeat-dose phase Ib study, patients were randomized to receive 2 injections 4 weeks apart (day 1 and day 29) of sham (no ocular penetration) or 2.5 mg ANX007 or 5.0 mg ANX007. Doses were administered at volumes of 20 μL (1 mg dose), 50 μL (2.5 mg dose), and 100 μL (5 mg dose), respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Sham procedure
“For the sham injection, the preparation was identical to injection with ANX007. The sham injection was performed by applying pressure to the eye at the location of a typical IVT injection using the blunt end of an empty syringe without a needle.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Registered phase 1b arms
Study outcomes
Rationale for using treatment-emergent adverse events as the primary endpoint
Registered primary and secondary outcomes of the phase 1b study
Safety assessments and follow-up in the phase 1b study
“In the repeat-dose phase Ib study, patients were followed for a total of 12 weeks for safety, tolerability, PK (unbound ANX007 concentration in serum and aqueous humor)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The safety assessments included AEs, vital signs, physical examination, urinalysis, complete blood count, serum chemistries, best corrected visual acuity assessment, slit-lamp examination, IOP measurement, and dilated fundoscopy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Aqueous humor C1q as a measure of retinal target engagement
“Inhibition of C1q in the aqueous humor is anticipated to represent inhibition of C1q in relevant sites of neurodegenerative ophthalmic disease within the retina.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In these animal studies, complete C1q target engagement in the aqueous humor reflected complete target engagement in the vitreous and retinal tissue, with measurable unbound drug at these sites in the back of the eye (Annexon, data on file).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Aqueous humor sampling and assays
“Aqueous humor was collected only in the phase Ib study per investigator standard of care into a tube provided for the study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Plate-captured C1q was detected using a monoclonal mouse anti-C1q antibody-alkaline phosphatase conjugate that binds to the same site as ANX007, thus enabling measurement of free C1q levels.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Statistical analysis description
Number of participants (Planned and analyzed)
Planned and enrolled participants in the phase 1b study
“Seventeen patients (mean Humphrey visual field deviation between −3 and −24 dB) were enrolled in phase Ib and randomized to 2 monthly doses of ANX007 (sham, n = 6; 2.5 mg ANX007, n = 6; or 5 mg ANX007, n = 5).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Description of analysis sets
Descriptive analysis without hypothesis testing
“No formal comparisons or hypothesis testing were planned for comparisons between dosing levels evaluated in either study, and data are presented descriptively throughout. Descriptive statistics for categorical variables included counts and percentages. Descriptive statistics for continuous variables included means, medians, standard deviation (SD), and minimum and maximum values.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Results
Participant disposition
Treated participants and early terminations in the phase 1b study
“In the phase Ib study, 18 patients were included in the study and 17 received study treatment. One patient was randomized to receive ANX007 2.5 mg but terminated participation in the study and did not receive any study treatment due to elevated IOP on day 1.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“One patient with pseudo-exfoliative glaucoma in the sham group terminated the study early after receiving the day 1 injection due to protocol violation (pseudo-exfoliation glaucoma was not recognized as included in primary open angle glaucoma inclusion criteria).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Baseline characteristics
Demographics of the phase 1b study by arm
Efficacy results
Aqueous humor C1q target engagement at day 29
“Correspondingly, mean (SD) and median (min, max) unbound C1q at day 1 (preinjection) was 100.1 (99.9) and 51.6 (16, 254) ng/ml in sham, 110.0 (109.5) and 65.7 (23, 293) in the ANX007 2.5 mg dose group, and 110.0 (83.1) and 86.8 (14, 222) in the ANX007 5.0 mg dose groups. Unbound C1q was reduced to undetectable levels at day 29 (< 0.6 ng/ml) in aqueous humor at both dose levels in all subjects (Fig 4).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Full engagement of C1q in the aqueous humor at day 29 in all treated subjects supports monthly or less-frequent dosing of ANX007 in future clinical studies.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Aqueous humor drug concentrations at day 29
“Mean (SD) and median (min, max) ANX007 levels in aqueous humor on day 29 were 911 ng/ml (846) and 631 (225, 2539) ng/ml in the ANX007 2.5 mg dose group and 5345 ng/ml (6351) and 3111 (413, 12 512) ng/ml in the ANX007 5.0 mg dose group (Fig 3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Systemic pharmacokinetics and pharmacodynamics after repeat dosing
“The PK and PD analyses conducted in the phase 1b study demonstrated detectable levels of ANX007 and corresponding complete reduction of free C1q in the aqueous humor following IVT injection with ANX007 at both the 2.5 and 5.0 mg dose levels through 29 days after the first injection. Importantly, no PK or PD changes were observed in the systemic circulation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Adverse events in the phase 1b study by arm
Serious, severe, and treatment-emergent adverse events after repeat dosing
“No serious AEs, severe TEAEs, or fatal AEs were reported in any group at any time during the study. A total of 6 TEAEs were reported, 2 events in each dose level. Treatment-emergent AEs included conjunctival hemorrhage, conjunctival hyperemia, eye irritation/pain, foreign body sensation in the eyes, ocular hyperemia, blurry vision, and 1 systemic TEAE of bronchitis, which was not assessed to be related to ANX007 (Table 2). All TEAEs were mild in severity and none resulted in study discontinuation. All resolved by study closure. No drug-specific safety signals were observed, and there were no clinically significant laboratory results during study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Intraocular pressure after repeat dosing
“Intraocular pressure returned to normal levels (≤ 21 mm Hg) within 45 minutes for all patients and within 30 minutes for 16/17 (94.1%) patients. Mean IOP measurements were within normal limits (≤ 21 mm Hg) at all time points.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Best corrected visual acuity through day 84
“Between baseline and day 84, the mean (SD) logarithm of the minimum angle of resolution results for the study eye decreased (representing improved visual acuity) in the Sham (−0.073 ± 0.0485) and ANX007 2.5 mg (−0.032 ± 0.1001) groups but increased (representing worsened visual acuity) in the ANX007 5.0 mg group (0.024 ± 0.0485) (Fig 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Anti-drug antibodies after repeat dosing
“Low levels of ADA positivity were detected in 7 patients (1 patient in the sham group, 3 patients in the ANX007 2.5 mg group, and 3 patients in the ANX007 5 mg group). The signal in the ADA assay was marginally above the cut points. Of these, 5 patients (1 patient in the sham group, 1 patient in the ANX007 2.5 mg group, and 3 patients in the ANX007 5 mg group) were ADA-positive at all time points, including the predosing period, without any dose-related changes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Study limitations
Summary: glaucoma population, small sample, and short follow-up
ANX007-GLA-02 enrolled participants with primary open-angle glaucoma, a population that differs from the geographic atrophy population of the phase 2 and phase 3 trials. Seventeen participants received study treatment (sham, 6; 2.5 mg, 6; 5 mg, 5), follow-up lasted 12 weeks with 2 injections given 4 weeks apart, and no formal comparisons or hypothesis testing were planned, so the results are descriptive. The safety table lists 7 participants in the 2.5-mg column and 18 overall, while the text reports 6 participants treated with 2.5 mg and 17 treated overall. Target engagement was measured in aqueous humor, which the authors state is “anticipated to represent” inhibition of C1q in the retina, supported by nonhuman primate data on file. The 5-mg dose was given in 100 μL in this study, while the ongoing phase 3 ARCHER II trial administers 5 mg in a 25-microliter dose. Low-level anti-drug antibody positivity was detected in 7 participants, including 1 in the sham group, which the authors attribute to likely false positives in the assay.
Author-stated limitations of the phase 1b study
“When considering the results of these data in a broader context, it should be noted that the relatively small sample size and descriptive nature of the analyses preclude formal clinical endpoint comparisons between the sham and treatment groups in the phase Ib study and also between the dose levels evaluated. Additional data from larger cohorts will add to our understanding of safety and efficacy at different dosing levels.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote